Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22089684 | 1.00 | CA12 (0.43) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL28408187 | 0.82 | CA12 (0.43) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL22089696 | 0.81 | CYP2D6 (0.47) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL22090243 | 0.81 | CYP2D6 (0.47) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL715065 | 0.81 | CYP2D6 (0.47) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL22089693 | 0.81 | CYP2D6 (0.47) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL3486690 | 0.78 | CA2 (0.50) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL28155896 | 0.78 | CA2 (0.50) | CA12CA2CA9CYP2D6MAPK1 | |
| SCHEMBL27189095 | 0.78 | CA2 (0.44) | CA12CA2CA9CYP2D6MAPK1 | |
| Norvaline SCHEMBL22749321 | 0.78 | KIF11 (0.47) | CA12CA2CA9CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-119118999-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118955477-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118903141-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118903142-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-12098142-B2 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-09-24 | — | — | US | disclosed |
| CN-113227074-B | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118388457-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118290403-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11981663-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-05-14 | — | — | US | disclosed |
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230416235-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-12-28 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220298144-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-3877381-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-113227074-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods | 凌科药业(杭州)有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020119819-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CA12 4726/4885CA2 3590/4885CA9 4299/4885 |
| US-20220298144-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CA12 4726/4885CA2 3590/4885CA9 4299/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | CA12 3428/4885CA2 2019/4885CA9 3238/4885 |
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CA12 4726/4885CA2 3590/4885CA9 4299/4885 |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CA12 4720/4885CA2 3558/4885CA9 4209/4885 |
| US-12098142-B2 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | CA12 4698/4885CA2 3715/4885CA9 4152/4885 |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CA12 4726/4885CA2 3590/4885CA9 4299/4885 |
| US-20230416235-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CA12 4726/4885CA2 3590/4885CA9 4299/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | CA12 4720/4885CA2 3558/4885CA9 4209/4885 |
| US-11981663-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CA12 4720/4885CA2 3558/4885CA9 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.